12.75

3.07% 0.38

Pre-market: 12.67 -0.08 -0.63%

Atrium Therapeutics Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Atrium Therapeutics Inc stock is traded at $12.75, with a volume of 261.51K. It is up +3.07% in the last 24 hours and down -3.63% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Previous Close:

$12.37

Open:

$12.4

24h Volume:

261.51K

Relative Volume:

0.81

Market Cap:

$218.10M

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-5.3684

EPS:

-2.375

Net Cash Flow:

$-502.70M

1W Performance:

+10.39%

1M Performance:

-3.63%

6M Performance:

-82.26%

1Y Performance:

-59.36%

1-Day Range:

$12.30

$12.76

1-Week Range:

$11.40

$12.76

52-Week Range:

$11.40

$73.06

Atrium Therapeutics Inc Stock (RNA) Company Profile

Name

Atrium Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

858-401-7900

Address

3020 CALLAN ROAD, SAN DIEGO, CA

Employee

391

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Atrium Therapeutics Inc	12.75	218.10M	10.73M	-455.74M	-502.70M	-2.375
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Initiated	Wells Fargo	Overweight
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Atrium Therapeutics Inc Stock (RNA) Latest News

Jun 08, 2026